Nanite develops next-generation, non-viral gene therapy delivery systems using AI-driven polymer design and in vivo screening. The company engineers tissue-specific polymer nanoparticles (PNPs) that offer advantages over traditional viral vectors and lipid nanoparticles. Their platform decodes polymer delivery rules through a closed-loop workflow combining high-throughput synthesis, biology, and artificial intelligence.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Current gene therapy methods using viral vectors and lipid nanoparticles (LNPs) face challenges related to safety, immunogenicity, and limited tissue specificity, hindering effective and targeted drug delivery. A deeper understanding of polymer-biology interactions is needed to overcome these limitations.
Solution
Nanite is developing programmable polymer nanoparticles (PNPs) for non-viral gene delivery, offering a safer and more effective alternative to traditional methods. Their approach combines high-throughput synthesis, multi-modal data generation, and AI-driven design to engineer PNPs with enhanced tissue-specific targeting. The SAYER platform uses a closed-loop system that integrates high-throughput synthesis, biology, materials science, and artificial intelligence to rationally design and synthesize PNPs, enabling the coherent engineering of precision delivery vectors. This technology aims to improve the efficacy and safety of genetic drug delivery by decoding polymer delivery mechanisms.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing gene therapies and targeted drug delivery systems.
Features
- Programmable polymer nanoparticles (PNPs) for targeted gene delivery
- AI-driven design for optimized polymer properties and tissue specificity
- High-throughput synthesis and screening platform (SAYER)
- Multi-modal data generation for comprehensive polymer characterization
- In vivo screening to validate tissue-specific delivery
- Virus-free gene therapy approach
- Resorbable polymer nanoparticles